Haller J. Smith
University of Alabama at Birmingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Haller J. Smith.
Gynecologic Oncology | 2015
Haller J. Smith; Christen L. Walters Haygood; Rebecca C. Arend; Charles A. Leath; J. Michael Straughn
PURPOSE To determine the cost-effectiveness of olaparib, a PARP inhibitor, as maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer. METHODS Two separate decision analysis models compared the cost of observation versus olaparib maintenance therapy in patients with PS recurrent ovarian cancer, one for patients with a germline BRCA1/2 mutation and one for patients with wild-type BRCA1/2. Patients received six cycles of paclitaxel and carboplatin. Drug costs were estimated using 2014-2015 wholesale acquisition costs. The cost of olaparib was estimated at
Oncotarget | 2017
T.B. Turner; Selene Meza-Perez; Angelina Londono; Ashwini A. Katre; Jacelyn E. Peabody; Haller J. Smith; Andres Forero; Lyse A. Norian; J. Michael Straughn; Donald J. Buchsbaum; Troy D. Randall; Rebecca C. Arend
13,440 per month. Rate of germline BRCA1/2 mutation was estimated at 20%. Progression-free survival was determined from published data. Incremental cost-effectiveness ratios (ICERs) per progression-free life-year saved (PF-LYS) were calculated. A sensitivity analysis estimated the cost at which olaparib would be cost-effective. RESULTS We estimated that there were 5549 patients diagnosed with PS recurrent ovarian cancer in the United States annually. The cost of observation in 1110 patients with a BRCA1/2 mutation was
Gynecologic Oncology | 2017
T.B. Turner; S.E. Dilley; Haller J. Smith; Warner K. Huh; Susan C. Modesitt; Stephen L. Rose; Laurel W. Rice; Jeffrey M. Fowler; J. Michael Straughn
5.5 million (M) versus
Gynecologic oncology reports | 2017
Haller J. Smith; J. Michael Straughn; Donald J. Buchsbaum; Rebecca C. Arend
169.2M for maintenance therapy with olaparib. The ICER for olaparib maintenance therapy in patients with a BRCA mutation was
Gynecologic Oncology | 2012
A. Ziebarth; Haller J. Smith; Mary E. Killian; Nguyet A. Nguyen; Jennifer Durst; Akila Subramaniam; Kenneth H. Kim; Charles A. Leath; J. Michael Straughn; Ronald D. Alvarez
258,864 per PF-LYS. If the cost of olaparib was decreased to
International Journal of Gynecological Cancer | 2013
Christen L. Walters; Kellie E. Schneider; Jenny M. Whitworth; Janelle M. Fauci; Haller J. Smith; Mack N. Barnes; J. Michael Straughn
2500 per month, the ICER was
Surgical Clinics of North America | 2018
Haller J. Smith; Charles A. Leath; J.M. Straughn
49,584. For the 4439 patients with wild-type BRCA, the cost of maintenance therapy was
Molecular Cancer Research | 2018
Rebecca C. Arend; Angelina Londono; Allison M. Montgomery; Haller J. Smith; Zachary C. Dobbin; Ashwini A. Katre; Alba Martinez; Eddy S. Yang; Ronald D. Alvarez; Warner K. Huh; Kerri S. Bevis; J. Michael Straughn; Jacob M. Estes; Lea Novak; David K. Crossman; Sara J. Cooper; Charles N. Landen; Charles A. Leath
444.2M; the ICER was
Gynecologic Oncology | 2018
Teresa Boitano; Haller J. Smith; T. Rushton; M.C. Johnston; J.M. Straughn; Charles A. Leath
600,552 per PF-LYS. CONCLUSIONS For patients with a germline BRCA1/2 mutation, maintenance therapy with olaparib is not cost-effective with an ICER of
Gynecologic Oncology | 2018
J. Michael Straughn; Teresa Boitano; Haller J. Smith; S.E. Dilley; Margaret I. Liang; Lea Novak
258,864 per PF-LYS. To achieve an ICER of less than
